SMA2h
Zolgensma into spinal canal drives SMA type 2 motor gains
The Phase 3 STEER trial enrolled more than 100 children with SMA type 2, ages 2-17, who were able to sit, but hadn't walked ...
FiercePharma3d
After delay with FDA, Novartis touts pivotal trial win for intrathecal Zolgensma in older SMA patients
More than three years after Novartis’ plan for a speedy approval for intrathecal Zolgensma was thwarted by an FDA requirement ...
pharmaphorum6d
New data could widen use of Novartis' SMA therapy Zolgensma
Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...
Positive data could expand use of Novartis’ gene therapy for SMA
On 30 December 2024, Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached ...
Novartis reports positive results for intrathecal Zolgensma
Novartis (NYSE:NVS) said a Phase 3 study of an intrathecal formulation of its gene therapy Zolgensma, also known as OAV101 IT ...
Novartis Says New Drug Helps Children With Rare Spinal Condition
Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the ...
Novartis gene therapy helps children with rare muscle disorder in study
Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle ...
Biogen Holds On, But Growth Slips Through Its Fingers
Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.
Becker's Spine Review5d
Novartis medication could treat spinal condition
Novartis is in the trial phase for a new experimental medicine that has shown promise in improving motor function in children with a form of spinal muscular atrophy, according to a Dec. 30 report from ...
Seeking Alpha7d
Novartis reports positive results for intrathecal Zolgensma
Novartis (NYSE:NVS) said a Phase 3 study of an intrathecal formulation of its gene therapy Zolgensma, also known as OAV101 IT, met its primary endpoint in the treatment of children with spinal ...
Detroit News6d
Novartis says new drug helps children with rare spinal condition
Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the devastating disorder targeted by its gene therapy Zolgensma ...
Yahoo Finance3d
Positive data could expand use of Novartis’ gene therapy for SMA
On 30 December 2024, Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached its primary endpoint in a Phase III study in paediatric patients aged ...